Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience | Zendy

Khan S. | Zendy; Karponis D. | Zendy; Wali G. | Zendy

Open Access

Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience

Author(s) -

Khan S.,

Karponis D.,

Wali G.

Publication year - 2021

Publication title -

skin health and disease

Language(s) - English

Resource type - Journals

ISSN - 2690-442X

DOI - 10.1002/ski2.54

Subject(s) - hidradenitis suppurativa , medicine , psoriasis , dermatology , pandemic , covid-19 , retrospective cohort study , plaque psoriasis , adalimumab , tertiary care , cohort , surgery , disease , pathology , infectious disease (medical specialty) , outbreak

Retrospective review data from 183 patients with psoriasis and/or hidradenitis suppurativa from a UK tertiary dermatology centre, suggests biologic therapy does not confer a significant increased risk of contracting severe Covid‐19 in this cohort. This is in line with a growing body of evidence which indicates that it is safe to continue using biologic therapies during the pandemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research